LOR 2040

Drug Profile

LOR 2040

Alternative Names: GTI-2040; LOR-2040

Latest Information Update: 04 Sep 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lorus Therapeutics
  • Developer Aptose Biosciences
  • Class Antineoplastics; Oligodeoxyribonucleotides
  • Mechanism of Action DNA synthesis inhibitors; Ribonucleotide reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Renal cancer
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Acute myeloid leukaemia; Bladder cancer; Breast cancer; Chronic myeloid leukaemia; Colorectal cancer; Myelodysplastic syndromes; Non-small cell lung cancer; Prostate cancer; Renal cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 04 Sep 2015 No recent reports on development identified - Phase-I for Chronic myeloid leukaemia in USA (IV)
  • 04 Sep 2015 No recent reports on development identified - Phase-I for Myelodysplastic syndromes in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top